Cargando…
Xiaoaiping injection combined with chemotherapy for advanced gastric cancer: An updated systematic review and meta-analysis
Aim: To evaluate the clinical efficacy and safety of Xiaoaiping injection combined with chemotherapy in the treatment of advanced gastric cancer by meta-analysis. Methods: Seven databases, including China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, Cochrane Library, Pub...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561863/ https://www.ncbi.nlm.nih.gov/pubmed/36249747 http://dx.doi.org/10.3389/fphar.2022.1023314 |
_version_ | 1784808040809103360 |
---|---|
author | Zhou, Xing Qin Chang, Ya Zhou Shen, Chao Yan Han, Jie Chang, Ren An |
author_facet | Zhou, Xing Qin Chang, Ya Zhou Shen, Chao Yan Han, Jie Chang, Ren An |
author_sort | Zhou, Xing Qin |
collection | PubMed |
description | Aim: To evaluate the clinical efficacy and safety of Xiaoaiping injection combined with chemotherapy in the treatment of advanced gastric cancer by meta-analysis. Methods: Seven databases, including China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, Cochrane Library, PubMed, Embase, and Web of Science, were searched by computer for randomized controlled clinical trials of Xiaoaiping injection combined with chemotherapy in the treatment of gastric cancer. Risk of bias assessment and meta-analysis were performed by Review Manager 5.3 software. Results: There were 16 articles that met the inclusion criteria, with a total of 1,236 patients, 617 in the observation group and 619 in the control group. The results of meta-analysis showed that the observation group was better than chemotherapy alone control group in RR [OR = 1.86, p < 0.00001]; disease control rate (DCR) [OR = 2.45, p < 0.00001]; Karnofsky performance status (KPS) score [OR = 3.21, p < 0.00001] or [MD = 7.73, p = 0.001]. In terms of biochemical indicators, Xiaoaiping significantly reduced inflammation factors level, including tumor necrosis factor alpha (TNF-α) [MD = −15.00, p < 0.00001]; interleukin-6 (IL-6) [MD = −13.00, p < 0.00001]; C-reaction protein (CRP) [MD = −5.80, p < 0.00001]. Xiaoaiping could enhance immune function, significantly reducing myeloid-derived suppressor cells (MDSCs) [MD = −6.20, p < 0.00001] and Treg [MD = −1.70, p < 0.00001]. Xiaoaiping injection combined with chemotherapy could significantly decrease tumor markers, including carcinoembryonic antigen (CEA) [MD = −11.64, p < 0.00001]; CA199 [MD = −33.57, p = 0.02]; CA242 [MD = −20.66, p < 0.00001]; CA125 [MD = −12.50, p = 0.0005]. In the comparison of adverse reactions, the incidence rate of Xiaoaiping injection group was significantly lower than that of control group. The funnel plot showed that the left and right sides are basically symmetrical, and it can be considered that there is no obvious publication bias. Conclusion: Xiaoaiping injection combined with chemotherapy has better curative effect and less adverse reactions in the treatment of gastric cancer. However, limited by the quality of the included studies, more high-quality studies are still needed to be verified. Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022353842], identifier [CRD42022353842]. |
format | Online Article Text |
id | pubmed-9561863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95618632022-10-15 Xiaoaiping injection combined with chemotherapy for advanced gastric cancer: An updated systematic review and meta-analysis Zhou, Xing Qin Chang, Ya Zhou Shen, Chao Yan Han, Jie Chang, Ren An Front Pharmacol Pharmacology Aim: To evaluate the clinical efficacy and safety of Xiaoaiping injection combined with chemotherapy in the treatment of advanced gastric cancer by meta-analysis. Methods: Seven databases, including China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, Cochrane Library, PubMed, Embase, and Web of Science, were searched by computer for randomized controlled clinical trials of Xiaoaiping injection combined with chemotherapy in the treatment of gastric cancer. Risk of bias assessment and meta-analysis were performed by Review Manager 5.3 software. Results: There were 16 articles that met the inclusion criteria, with a total of 1,236 patients, 617 in the observation group and 619 in the control group. The results of meta-analysis showed that the observation group was better than chemotherapy alone control group in RR [OR = 1.86, p < 0.00001]; disease control rate (DCR) [OR = 2.45, p < 0.00001]; Karnofsky performance status (KPS) score [OR = 3.21, p < 0.00001] or [MD = 7.73, p = 0.001]. In terms of biochemical indicators, Xiaoaiping significantly reduced inflammation factors level, including tumor necrosis factor alpha (TNF-α) [MD = −15.00, p < 0.00001]; interleukin-6 (IL-6) [MD = −13.00, p < 0.00001]; C-reaction protein (CRP) [MD = −5.80, p < 0.00001]. Xiaoaiping could enhance immune function, significantly reducing myeloid-derived suppressor cells (MDSCs) [MD = −6.20, p < 0.00001] and Treg [MD = −1.70, p < 0.00001]. Xiaoaiping injection combined with chemotherapy could significantly decrease tumor markers, including carcinoembryonic antigen (CEA) [MD = −11.64, p < 0.00001]; CA199 [MD = −33.57, p = 0.02]; CA242 [MD = −20.66, p < 0.00001]; CA125 [MD = −12.50, p = 0.0005]. In the comparison of adverse reactions, the incidence rate of Xiaoaiping injection group was significantly lower than that of control group. The funnel plot showed that the left and right sides are basically symmetrical, and it can be considered that there is no obvious publication bias. Conclusion: Xiaoaiping injection combined with chemotherapy has better curative effect and less adverse reactions in the treatment of gastric cancer. However, limited by the quality of the included studies, more high-quality studies are still needed to be verified. Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022353842], identifier [CRD42022353842]. Frontiers Media S.A. 2022-09-30 /pmc/articles/PMC9561863/ /pubmed/36249747 http://dx.doi.org/10.3389/fphar.2022.1023314 Text en Copyright © 2022 Zhou, Chang, Shen, Han and Chang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhou, Xing Qin Chang, Ya Zhou Shen, Chao Yan Han, Jie Chang, Ren An Xiaoaiping injection combined with chemotherapy for advanced gastric cancer: An updated systematic review and meta-analysis |
title | Xiaoaiping injection combined with chemotherapy for advanced gastric cancer: An updated systematic review and meta-analysis |
title_full | Xiaoaiping injection combined with chemotherapy for advanced gastric cancer: An updated systematic review and meta-analysis |
title_fullStr | Xiaoaiping injection combined with chemotherapy for advanced gastric cancer: An updated systematic review and meta-analysis |
title_full_unstemmed | Xiaoaiping injection combined with chemotherapy for advanced gastric cancer: An updated systematic review and meta-analysis |
title_short | Xiaoaiping injection combined with chemotherapy for advanced gastric cancer: An updated systematic review and meta-analysis |
title_sort | xiaoaiping injection combined with chemotherapy for advanced gastric cancer: an updated systematic review and meta-analysis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561863/ https://www.ncbi.nlm.nih.gov/pubmed/36249747 http://dx.doi.org/10.3389/fphar.2022.1023314 |
work_keys_str_mv | AT zhouxingqin xiaoaipinginjectioncombinedwithchemotherapyforadvancedgastriccanceranupdatedsystematicreviewandmetaanalysis AT changyazhou xiaoaipinginjectioncombinedwithchemotherapyforadvancedgastriccanceranupdatedsystematicreviewandmetaanalysis AT shenchaoyan xiaoaipinginjectioncombinedwithchemotherapyforadvancedgastriccanceranupdatedsystematicreviewandmetaanalysis AT hanjie xiaoaipinginjectioncombinedwithchemotherapyforadvancedgastriccanceranupdatedsystematicreviewandmetaanalysis AT changrenan xiaoaipinginjectioncombinedwithchemotherapyforadvancedgastriccanceranupdatedsystematicreviewandmetaanalysis |